Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

Poster applications for the 2025 Office of Interdisciplinary Graduate Program's (OIGP) Spring Reception are now closed. Our reception will take place in-person this year on May 7th, 2025 from 9:30 a.m ...

NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory ...